{"id":3041,"date":"2026-07-09T17:31:57","date_gmt":"2026-07-09T15:31:57","guid":{"rendered":"https:\/\/appligoutte.io\/?page_id=3041"},"modified":"2026-07-09T19:30:19","modified_gmt":"2026-07-09T17:30:19","slug":"actualites-medicales","status":"publish","type":"page","link":"https:\/\/appligoutte.io\/index.php\/actualites-medicales\/","title":{"rendered":"Actualit\u00e9s m\u00e9dicales"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3041\" class=\"elementor elementor-3041\">\n\t\t\t\t<div class=\"elementor-element elementor-element-20842a44 max-width e-flex e-con-boxed e-con e-parent\" data-id=\"20842a44\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;none&quot;,&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-1e268cfd e-con-full e-flex e-con e-child\" data-id=\"1e268cfd\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-72f09f56 elementor-widget elementor-widget-heading\" data-id=\"72f09f56\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Actualit\u00e9s m\u00e9dicales<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7bcea6f1 e-flex e-con-boxed e-con e-parent\" data-id=\"7bcea6f1\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1650dac1 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"1650dac1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-57a79d28 e-flex e-con-boxed e-con e-parent\" data-id=\"57a79d28\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7e29da86 elementor-widget elementor-widget-heading\" data-id=\"7e29da86\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><span style=\"font-size:18px;line-height: 0;margin-right: 4px\">\u2022<\/span> JUIN 2026<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-46fb4252 elementor-widget elementor-widget-heading\" data-id=\"46fb4252\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Goutte et comorbidit\u00e9s cardior\u00e9nales : <br>o\u00f9 en est-on ?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2209f04 elementor-widget elementor-widget-text-editor\" data-id=\"2209f04\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Il a \u00e9t\u00e9 d\u00e9montr\u00e9 depuis 2010 environ dans la litt\u00e9rature que les <strong>patients goutteux pr\u00e9sentent un nombre significatif de comorbidit\u00e9s cardiovasculaires s\u00e9v\u00e8res.<\/strong><\/p><p>En effet, dans l\u2019\u00e9tude prospective GOSPEL men\u00e9e par le Pr Liot\u00e9 en France de 2008 \u00e0 2009, sur environ 1000 patients, 54 % souffraient d\u2019hypertension, 47 % de dyslipid\u00e9mie, 15 % d\u2019hyperglyc\u00e9mie ou diab\u00e8te et pr\u00e8s de 43 % des patients avaient une insuffisance r\u00e9nale chronique de stade 3 \u00e0 5 (1)<\/p><p>Aussi, nous savons que la <strong>pr\u00e9valence de la goutte augmente avec l\u2019intensit\u00e9 de la maladie r\u00e9nale chronique\u00a0: <\/strong>en effet, dans une \u00e9tude publi\u00e9e en 2015 portant sur une grande cohorte de patients allemands porteurs d\u2019une insuffisance r\u00e9nale chronique de stade variable, la pr\u00e9valence globale de la goutte \u00e9tait de 24,3 % ; elle passait de 16,0 % chez les personnes pr\u00e9sentant un DFG estim\u00e9 \u2265 60 ml\/min\/1,73 m\u00b2 \u00e0 35,6 % chez celles dont le DFG estim\u00e9 \u00e9tait &lt; 30. (2)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-87c454b elementor-widget elementor-widget-n-accordion\" data-id=\"87c454b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1420\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-1420\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Lire la suite <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"fas fa-plus\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1420\" class=\"elementor-element elementor-element-cda4c9f e-con-full e-flex e-con e-child\" data-id=\"cda4c9f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1420\" class=\"elementor-element elementor-element-4aafa35 e-flex e-con-boxed e-con e-child\" data-id=\"4aafa35\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1420\" class=\"elementor-element elementor-element-cb33c1c e-con-full e-flex e-con e-child\" data-id=\"cb33c1c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d9b1d2a elementor-widget elementor-widget-image\" data-id=\"d9b1d2a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"934\" height=\"450\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-1.jpg\" class=\"attachment-large size-large wp-image-3056\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-1.jpg 934w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-1-300x145.jpg 300w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-1-768x370.jpg 768w\" sizes=\"(max-width: 934px) 100vw, 934px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e96ed11 elementor-widget elementor-widget-text-editor\" data-id=\"e96ed11\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>R\u00e9ciproquement<b>, le risque de d\u00e9velopper une insuffisance r\u00e9nale terminale (IRT) chez les patients atteints de goutte est accru,<\/b> et ceci a \u00e9t\u00e9 mis en \u00e9vidence au sein d&rsquo;une cohorte repr\u00e9sentative \u00e0 Ta\u00efwan. Les taux d&rsquo;incidence de l&rsquo;IRT \u00e9taient de 1,73 cas pour 1 000 ann\u00e9es-patients dans le groupe goutteux (vs 0,41 dans le groupe contr\u00f4le). Apr\u00e8s ajustement, la goutte \u00e9tait associ\u00e9e \u00e0 un rapport de risque (HR) de 1,57 pour l&rsquo;IRT (soit une augmentation du risque de 57%). (3)<\/p><p><b style=\"color: #000000; font-family: Calibri, sans-serif; font-size: 11pt;\">Des \u00e9tudes de cohorte r\u00e9centes, publi\u00e9es en 2022, indiquent que la goutte est associ\u00e9e \u00e0 un risque accru d&rsquo;\u00e9v\u00e9nements cardiovasculaires<\/b><span style=\"color: #000000; font-family: Calibri, sans-serif; font-size: 11pt;\"> (rapport de risque ajust\u00e9 de 1,34 chez les femmes ; 1,18 chez les hommes.) <\/span>De plus, chez les hommes goutteux sans ant\u00e9c\u00e9dent de maladie cardiovasculaire, le risque cardiovasculaire \u00e9tait plus faible chez ceux sous allopurinol et chez ceux dont les taux s\u00e9riques d&rsquo;urate se situaient dans la fourchette th\u00e9rapeutique recommand\u00e9e. (4)\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-17f9f6a elementor-widget elementor-widget-image\" data-id=\"17f9f6a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"945\" height=\"522\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-2.jpg\" class=\"attachment-large size-large wp-image-3057\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-2.jpg 945w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-2-300x166.jpg 300w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-2-768x424.jpg 768w\" sizes=\"(max-width: 945px) 100vw, 945px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dbb143b elementor-widget elementor-widget-text-editor\" data-id=\"dbb143b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Aussi, dans une grande \u00e9tude observationnelle r\u00e9trospective type cas-t\u00e9moins, on a observ\u00e9 que les patients ayant subi des \u00e9v\u00e9nements cardiovasculaires, par rapport \u00e0 ceux qui n&rsquo;en avaient pas subi, pr\u00e9sentaient un risque significativement plus \u00e9lev\u00e9 de crise de goutte au cours des 60 jours pr\u00e9c\u00e9dents (OR ajust\u00e9 de 1.93). (5) <strong>Ces r\u00e9sultats sugg\u00e8rent que les crises de goutte sont associ\u00e9es \u00e0 une augmentation transitoire des accidents cardiovasculaires apr\u00e8s la crise, <\/strong>\u00e9galement soulign\u00e9e dans une autre \u00e9tude (risque accru d\u2019\u00e9v\u00e9nements cardiovasculaires +55% dans les 30 jours qui suivent une premi\u00e8re crise (6)).<\/p><p><u>Effets b\u00e9n\u00e9fiques des traitements\u00a0: <\/u><\/p><p>L&rsquo;inhibiteur de l&rsquo;IL-1 et la colchicine ont \u00e9t\u00e9 associ\u00e9s \u00e0 une diminution des risques d&rsquo;insuffisance cardiaque (RR = 0,38), et d&rsquo;AVC (RR = 0,47), respectivement. (7)<\/p><p><strong>Chez les patients atteints de goutte entamant un traitement hypouric\u00e9miant, le risque d&rsquo;\u00e9v\u00e9nements cardiovasculaires \u00e9tait r\u00e9duit chez ceux b\u00e9n\u00e9ficiant d\u2019une prophylaxie par colchicine <\/strong>par rapport \u00e0 ceux ne recevant pas de prophylaxie (r\u00e9duction relative du risque de 18%) (8).<\/p><p><u>Facteurs associ\u00e9s aux crises de goutte\u00a0:<\/u><\/p><ul><li>La masse de d\u00e9p\u00f4ts de cristaux d\u2019urate monosodique, estim\u00e9e par \u00e9chographie<\/li><li>La consommation d&rsquo;alcool d\u00e9clenche des crises de goutte r\u00e9currentes, surtout dans les 24 heures suivant<\/li><li>La consommation de purines alimentaires<\/li><li>L\u2019introduction r\u00e9cente de diur\u00e9tiques<\/li><li>L\u2019arr\u00eat de la prophylaxie par COLCHICINE<\/li><\/ul><p><u>Des arguments pour abaisser la cible d\u2019uric\u00e9mie\u00a0?<\/u><\/p><p>Des donn\u00e9es montrent qu\u2019une uric\u00e9mie cible entre 50-60 mg\/L ne permet pas de dissoudre les cristaux d\u00e9pos\u00e9s. Elle emp\u00eache la formation d\u2019autres cristaux (9). <strong>On sait par ailleurs que la persistance des d\u00e9p\u00f4ts d\u2019urate est responsable des crises, qui sont associ\u00e9es \u00e0 un risque augment\u00e9 d\u2019\u00e9v\u00e9nements cardiovasculaires.<\/strong><\/p><p>Obtenir, au d\u00e9but du traitement hypo-uric\u00e9miant, une uric\u00e9mie cible inf\u00e9rieure \u00e0 40 mg\/L pourra permettre une dissolution plus rapide des d\u00e9p\u00f4ts et, ainsi, acc\u00e9l\u00e9rer la gu\u00e9rison des patients, ce qui r\u00e9duira probablement aussi le risque cardiovasculaire.<\/p><p><u>Le THU ralentit-il la progression de la maladie r\u00e9nale ? <\/u><\/p><p>L\u2019analyse post hoc issue de l&rsquo;essai \u00ab Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) \u00bb, s\u2019est concentr\u00e9e sur le taux de variation du d\u00e9bit de filtration glom\u00e9rulaire estim\u00e9 chez les patients atteints de goutte ayant re\u00e7u un traitement hypouric\u00e9miant par f\u00e9buxostat ou allopurinol. L&rsquo;analyse a r\u00e9v\u00e9l\u00e9 que, sur une dur\u00e9e m\u00e9diane de l&rsquo;\u00e9tude de 2,5 ans, 65 % des patients n&rsquo;ont pas pr\u00e9sent\u00e9 de baisse du d\u00e9bit de filtration glom\u00e9rulaire estim\u00e9 lors de multiples mesures. De plus, le<strong> maintien d\u2019uric\u00e9mies basses pendant le traitement hypouric\u00e9miant \u00e9tait significativement associ\u00e9 \u00e0 une diminution du risque de progression de la maladie r\u00e9nale chronique chez les patients atteints de goutte<\/strong> (10).<\/p><p>D\u2019apr\u00e8s les r\u00e9sultats d\u2019une grosse cohorte de pr\u00e8s de 14 000 patients, le risque \u00e0 5 ans de d\u00e9velopper une maladie r\u00e9nale grave ou en phase terminale \u00e9tait de 10,32 % chez les patients ayant atteint la cible d\u2019uric\u00e9mie (vs 12,73 % chez ceux qui ne l\u2019avaient pas atteinte). <strong>En d\u2019autres termes, atteindre la cible d\u2019uric\u00e9mie diminue de 11% le risque d\u2019\u00e9volution vers une maladie r\u00e9nale chronique s\u00e9v\u00e8re.(11)<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0c28ab4 elementor-widget elementor-widget-image\" data-id=\"0c28ab4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"945\" height=\"432\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-3.jpg\" class=\"attachment-large size-large wp-image-3058\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-3.jpg 945w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-3-300x137.jpg 300w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-3-768x351.jpg 768w\" sizes=\"(max-width: 945px) 100vw, 945px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c84c4bc elementor-widget elementor-widget-text-editor\" data-id=\"c84c4bc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><u>L\u2019atteinte d\u2019une uric\u00e9mie cible &lt;60 mg\/L gr\u00e2ce au THU permet-elle de r\u00e9duire le risque cardiovasculaire chez les patients atteints de goutte\u00a0?<\/u><\/p><p>Dans cette \u00e9tude de cohorte men\u00e9e aupr\u00e8s de patients goutteux trait\u00e9s par THU, l<strong>&lsquo;atteinte d\u2019un taux d&rsquo;urate s\u00e9rique inf\u00e9rieur \u00e0 60 mg\/L dans les 12 mois a \u00e9t\u00e9 associ\u00e9e \u00e0 un risque plus faible d&rsquo;\u00e9v\u00e9nements cardiovasculaires ind\u00e9sirables majeurs \u00e0 5 ans.<\/strong> En effet, les patients du groupe \u00ab\u00a0T2T (treat-to-target\u00a0\u00bb ou encore adaptation du traitement hypouric\u00e9miant jusqu\u2019\u00e0 la cible souhait\u00e9e d\u2019uric\u00e9mie) pr\u00e9sentaient un taux de survie \u00e0 5 ans plus \u00e9lev\u00e9 (diff\u00e9rence de survie pond\u00e9r\u00e9e : 1,0 % ) et un risque plus faible d&rsquo;\u00e9v\u00e9nements cardiovasculaires ind\u00e9sirables majeurs (rapport de risque pond\u00e9r\u00e9 : 0,91) que ceux du groupe sans strat\u00e9gie \u00e0 la cible (12)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9bfbd07 elementor-widget elementor-widget-image\" data-id=\"9bfbd07\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"945\" height=\"299\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-4.jpg\" class=\"attachment-large size-large wp-image-3059\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-4.jpg 945w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-4-300x95.jpg 300w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-4-768x243.jpg 768w\" sizes=\"(max-width: 945px) 100vw, 945px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0706f26 elementor-widget elementor-widget-text-editor\" data-id=\"0706f26\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><u>Comment traiter (et pr\u00e9venir) les crises de goutte chez patients avec une maladie r\u00e9nale chronique ?<\/u><\/p><p>Chez les patients au stade de MRC &lt;3 (soit un DFG &gt;30 mL\/min), la colchicine reste le traitement \u00e0 privil\u00e9gier pour la crise de goutte.<\/p><p>En dessous de 30 mL\/min de DFG (stades 4 et 5), on pr\u00e9f\u00e8rera utiliser les anti-IL1 ou la corticoth\u00e9rapie syst\u00e9mique.<\/p><p>Par ailleurs, les donn\u00e9es d\u2019une \u00e9tude multicentrique et prospective, FORTUNE-1, sugg\u00e8rent qu&rsquo;une <strong>augmentation progressive de la dose de f\u00e9buxostat, associ\u00e9e \u00e0 une prophylaxie \u00e0 faible dose de colchicine, a permis de r\u00e9duire efficacement les crises de goutte<\/strong> par rapport \u00e0 l&rsquo;administration de f\u00e9buxostat \u00e0 dose fixe en monoth\u00e9rapie. Aussi, l\u2019augmentation progressive de la dose de f\u00e9buxostat pourrait constituer une alternative efficace \u00e0 la prophylaxie \u00e0 faible dose de colchicine lors de la mise en place d&rsquo;un traitement hypouric\u00e9miant. (13)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-389159a elementor-widget elementor-widget-image\" data-id=\"389159a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"709\" height=\"519\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-5.jpg\" class=\"attachment-large size-large wp-image-3060\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-5.jpg 709w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-5-300x220.jpg 300w\" sizes=\"(max-width: 709px) 100vw, 709px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9e9583d elementor-widget elementor-widget-image\" data-id=\"9e9583d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"623\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-6-768x623.jpg\" class=\"attachment-medium_large size-medium_large wp-image-3061\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-6-768x623.jpg 768w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-6-300x243.jpg 300w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-6.jpg 987w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5d9d534 elementor-widget elementor-widget-image\" data-id=\"5d9d534\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"281\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-7-300x281.jpg\" class=\"attachment-medium size-medium wp-image-3062\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-7-300x281.jpg 300w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-7-768x719.jpg 768w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/schema-7.jpg 774w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0609764 elementor-widget elementor-widget-text-editor\" data-id=\"0609764\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><u>Quelle diff\u00e9rence d\u2019efficacit\u00e9 entre Allopurinol et Febuxostat\u00a0?<\/u><\/p><p>Dans l\u2019\u00e9tude STOP Gout, men\u00e9e sur pr\u00e8s de 900 participants, l&rsquo;allopurinol et le f\u00e9buxostat ont permis d&rsquo;atteindre les objectifs d\u2019uric\u00e9mie cible gr\u00e2ce \u00e0 une strat\u00e9gie d\u2019augmentation progressive de doses (sur 5 mois et demi environ). <strong>L&rsquo;allopurinol s&rsquo;est r\u00e9v\u00e9l\u00e9 non inf\u00e9rieur au f\u00e9buxostat dans la pr\u00e9vention des crises. <\/strong>Des r\u00e9sultats similaires ont \u00e9t\u00e9 observ\u00e9s chez les participants atteints d&rsquo;une insuffisance r\u00e9nale chronique de stade 3. (14).\u00a0<\/p><p>Conclusion\u00a0:<\/p><p><strong><u>Protocole d\u2019initiation et l\u2019adaptation posologique progressive, jusqu\u2019\u00e0 atteindre la cible d\u2019uric\u00e9mie (\u00ab\u00a0treat-to-target ou T2T\u00a0\u00bb) des inhibiteurs de xanthine oxydase (\u00e0 d\u00e9buter \u00e0 distance d\u2019une crise de goutte).<\/u><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2090dd7 elementor-widget elementor-widget-image\" data-id=\"2090dd7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"344\" src=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/Schema-8-768x344.png\" class=\"attachment-medium_large size-medium_large wp-image-3070\" alt=\"\" srcset=\"https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/Schema-8-768x344.png 768w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/Schema-8-300x134.png 300w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/Schema-8-1024x458.png 1024w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/Schema-8-1536x687.png 1536w, https:\/\/appligoutte.io\/wp-content\/uploads\/2026\/07\/Schema-8.png 1799w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-add7605 elementor-widget elementor-widget-text-editor\" data-id=\"add7605\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>(1) Liot\u00e9 F, Lancrenon S, Lanz S, Ea HK, Lambert C, Guggenbuhl P, et al. GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n = 1003). Joint Bone Spine. 2012 Oct;79(5):464-70. doi:10.1016\/j.jbspin.2011.09.014.<\/p><p>(2) Jing J, Kielstein JT, Schultheiss UT, Sitter T, Titze SI, Schaeffner ES, McAdams-DeMarco M, Kronenberg F, Eckardt KU, K\u00f6ttgen A, for the GCKD Study Investigators. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant. 2015;30(4):613-21. doi:10.1093\/ndt\/gfu352.<\/p><p>(3) Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Chiou MJ. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):R83. doi:10.1186\/ar3806.<\/p><p>(4) Cai K, Cumming T, Doherty M, Singh JA, Dalbeth N, Stamp LK, et al. Association between gout and cardiovascular outcomes in adults with no history of cardiovascular disease: large data linkage study in New Zealand. BMJ Med. 2022 Jun 22;1(1):e000081. doi:10.1136\/bmjmed-2021-000081.<\/p><p>(5)Cipolletta E, Tata LJ, Nakafero G, Mamas MA, Abhishek A. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA. 2022;328(5):440-450. doi:10.1001\/jama.2022.11390.<\/p><p>(6) Cipolletta E, Nakafero G, Richette P, Avery AJ, Mamas MA, Tata LJ, Abhishek A. Short-Term Risk of Cardiovascular Events in People Newly Diagnosed With Gout. Arthritis Rheumatol. 2025;77(2):244-253. doi:10.1002\/art.42986<\/p><p>(7) Li Z, Lin C, Cai X, Hu S, Lv F, Yang W, Zhu X, Ji L. Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis. 2023;379:117-126. doi:10.1016\/j.atherosclerosis.2023.06.972.<\/p><p>(8) Cipolletta E, Nakafero G, Mamas MA, Avery AJ, Tata LJ, Abhishek A. Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol. 2025;7(3):e201-e210. doi:10.1016\/S2665-9913(24)00309-1.<\/p><p>(9) Kelly B, Gamble GD, Horne A, Doyle AJ, Drake J, Aati O, Son CN, Kalluru R, Latto K, Stamp LK, Dalbeth N. Relationship between serum urate and changes in dual-energy CT monosodium urate crystal volume over 1 year in people with gout: an individual participant data analysis. Semin Arthritis Rheum. 2022;54:152001. doi:10.1016\/j.semarthrit.2022.152001.<\/p><p>(10) Ghang B, Park J, Lee JS, Lim JS, Kim H, Liew DFL, Kim J, Kang DH, Yoo B. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int. 2025 Mar;107(3):521-529. doi:10.1016\/j.kint.2024.10.022.\u00a0<\/p><p>(11) Wang Y, Dalbeth N, Terkeltaub R, et al. Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease. JAMA Intern Med. 2025;185(1):74-82. doi:10.1001\/jamainternmed.2024.6212. Epub 2024 Nov 25.<\/p><p>(12) Cipolletta E, et al. Treat-to-target urate-lowering treatment and cardiovascular outcomes in patients with gout. JAMA Intern Med. 2026;186(3):332-342. doi:10.1001\/jamainternmed.2025.7453.<\/p><p>(13) Yamanaka H, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270-276. doi:10.1136\/annrheumdis-2017-211574.<\/p><p>(14) O&rsquo;Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM Evid. 2022;1(3):EVIDoa2100028. doi:10.1056\/EVIDoa2100028<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f0f6f38 e-con-full e-flex e-con e-child\" data-id=\"f0f6f38\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-15c58149 max-width elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile e-flex e-con-boxed e-con e-parent\" data-id=\"15c58149\" data-element_type=\"container\" data-e-type=\"container\" id=\"fonctionnement\" data-settings=\"{&quot;animation&quot;:&quot;none&quot;,&quot;background_background&quot;:&quot;gradient&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-4adf89c5 e-con-full e-flex e-con e-child\" data-id=\"4adf89c5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-79283f4a elementor-widget elementor-widget-heading\" data-id=\"79283f4a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><span style=\"font-size:18px;line-height: 0;margin-right: 4px\">\u2022<\/span> Comment \u00e7a marche<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-251058ce elementor-widget elementor-widget-heading\" data-id=\"251058ce\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Seulement en<br>quelques \u00e9tapes<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-42e241bc elementor-widget elementor-widget-button\" data-id=\"42e241bc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">T\u00e9l\u00e9charger l'application<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-28b7333c e-con-full e-flex e-con e-child\" data-id=\"28b7333c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4f9bf482 elementor-widget elementor-widget-n-accordion\" data-id=\"4f9bf482\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1330\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-1330\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Installez l'application <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"fas fa-plus\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1330\" class=\"elementor-element elementor-element-74d02d60 e-con-full e-flex e-con e-child\" data-id=\"74d02d60\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1331\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1331\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Rentrez vos informations <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"fas fa-plus\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1331\" class=\"elementor-element elementor-element-18efe731 e-con-full e-flex e-con e-child\" data-id=\"18efe731\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1332\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1332\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Tenez \u00e0 jour votre taux d'acide urique <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"fas fa-plus\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1332\" class=\"elementor-element elementor-element-52beb37a e-con-full e-flex e-con e-child\" data-id=\"52beb37a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1333\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"4\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1333\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Adaptez votre traitement de fond <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"fas fa-plus\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1333\" class=\"elementor-element elementor-element-184ef63 e-flex e-con-boxed e-con e-child\" data-id=\"184ef63\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1334\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"5\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1334\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Apprenez \u00e0 pr\u00e9venir vos crises <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"fas fa-minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"fas fa-plus\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1334\" class=\"elementor-element elementor-element-34dc6f27 e-flex e-con-boxed e-con e-child\" data-id=\"34dc6f27\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Actualit\u00e9s m\u00e9dicales \u2022 JUIN 2026 Goutte et comorbidit\u00e9s cardior\u00e9nales : o\u00f9 en est-on ? Il a \u00e9t\u00e9 d\u00e9montr\u00e9 depuis 2010 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"site-sidebar-layout":"no-sidebar","site-content-layout":"","ast-site-content-layout":"full-width-container","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-3041","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/pages\/3041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/comments?post=3041"}],"version-history":[{"count":32,"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/pages\/3041\/revisions"}],"predecessor-version":[{"id":3089,"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/pages\/3041\/revisions\/3089"}],"wp:attachment":[{"href":"https:\/\/appligoutte.io\/index.php\/wp-json\/wp\/v2\/media?parent=3041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}